WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the AMPLIFY Phase III trial showed AstraZeneca’s CALQUENCE ® (acalabrutinib) in combination with venetoclax demonstrated a statistically ...
SAN DIEGO—Just over a year after approval, AstraZenca’s Calquence is giving Johnson & Johnson and AbbVie’s Imbruvica a run for its money in mantle cell lymphoma. But the British drugmaker doesn’t want ...
As AbbVie and Johnson & Johnson’s Imbruvica retreated, AstraZeneca’s Calquence has become the first BTK inhibitor to claim a unique win in previously untreated mantle cell lymphoma (MCL). Calquence, ...
WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s supplemental New Drug Application (sNDA) for CALQUENCE® (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Positive results from the ECHO Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab demonstrated a ...
There was no major difference in progression-free survival between patients with relapsed/refractory chronic lymphocytic leukemia who were treated with Calquence or Brukinsa. Patients treated with ...
Long-term study results show that outcomes, such as survival and response rates, in patients who have received Calquence-containing treatment regimens continue to outpace outcomes in those who were ...
Calquence (acalabrutinib) is prescribed for specific blood cancers, such as chronic lymphocytic leukemia (CLL). It works by targeting certain cancer cell features to slow their growth. The typical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results